12:00 AM
 | 
Oct 14, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

ALKS 5461 regulatory update

Alkermes said FDA granted Fast Track designation to ALKS 5461 as an adjunct to treat refractory major depressive disorder...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >